
Stock·NASDAQ·Healthcare
Amgen Inc. (AMGN)
- Market cap
- $235.64B
- P/E
- 25.25
- Dividend yield
- 2.31%
- Street target
- $440.00median of 34 analysts
- 52-week range
- $312.39 $483.99
What moved Amgen Inc. (AMGN)
Market figures as of November 20, 2026.
Was it the market or the company?
On November 20, 2026, AMGN fell 0.72%. The same day the S&P 500 (SPY) fell 3.64%, the Nasdaq 100 (QQQ) fell 5.67% and the health care sector (XLV) fell 0.12%.
The move was in line with the market. AMGN's one-year beta to SPY is 0.51, so SPY's -3.64% would on average have meant -1.85% for AMGN, close to what it did (1.1 percentage points less).
Over the last 20 sessions AMGN is down 0.82% against -9.23% for SPY, 8.4 percentage points ahead of it.
The wider market on November 20, 2026: CNBC reported that the sell-off's breaking point came with Anthropic's initial public offering and heavier selling in Nvidia, which it named as the first of five forces behind the drop. (CNBC, November 20, 2026)
| That day | 5 sessions | 20 sessions | |
|---|---|---|---|
| AMGN | -0.72% | -6.45% | -0.82% |
| S&P 500 (SPY) | -3.64% | -8.56% | -9.23% |
| Nasdaq 100 (QQQ) | -5.67% | -10.51% | -13.62% |
| Health care sector (XLV) | -0.12% | -6.15% | -1.14% |
Calculated by CleaRank from daily closes. Beta is measured on the last year of daily returns against SPY. A description of what happened, not a forecast.
AMGN stock today, November 22, 2026: price, news and analyst targets
As of November 20, 2026, Amgen Inc. (AMGN) trades at $435.64. Wall Street's median 12-month price target is $440.00 across 34 analysts, 1.0% above the price. CleaRank rates it Buy with a score of 71/100.
Amgen's stock has pulled back after a volatile week, falling 6.45% over the last week and 3.07% on November 18, 2026, when it closed at $443.89. It still trades 33.10% higher year to date and 13.62% above its 200-day average, and it sits in the upper part of its 52-week range. Analysts are split: the median 12-month target is $440.00, almost exactly where the stock trades, and the consensus rating is Hold. The company reported third-quarter adjusted EPS of $6.45 on November 3, 2026, beating the $5.78 estimate, and the shares rose 3.73% the next session.
Why the stock fell this week
Shares fell 6.45% over the past week, including a 3.07% drop on November 18, 2026, when the stock closed at $443.89. The decline is best read as a short-term pullback after a strong year rather than a change in the earnings picture. Over one month the stock is down only 0.62%, and over six months it is up 28.39%.
Earnings have beaten estimates
Amgen has beaten the EPS estimate in each of its last eight reports, including the November 3, 2026 report, where adjusted EPS of $6.45 came in 11.59% above the $5.78 estimate. The stock rose 3.73% in the first session after that report. Not every beat was rewarded: three of the eight beats were followed by a lower share price in the first session, so a beat alone has not reliably lifted the stock.
Valuation and balance sheet
The trailing P/E of 25.25 is at a discount to peers, sitting 20.8% below the sector median of 31.9. The price-to-sales ratio of 6.06 is well above the sector median of 3.4, and the stock trades with a return on equity of 78.35% against a sector median of 7.3%. Debt is high, with a debt-to-equity ratio of 3.76, and the trailing dividend yield is 2.31% on an annual dividend of $10.08. The stock beats the market's risk profile with a beta of 0.42 against the S&P 500.
Analysts are divided
Of 34 analysts, 11 rate the stock buy or strong buy, 18 hold it and 5 sell it. Three months ago 14 of 34 rated it buy. In the most recent actions, Argus Research kept its Buy rating on November 12, 2026, and UBS kept its Buy rating on November 4, 2026, while Freedom Broker downgraded the stock to Hold from Buy on November 6, 2026. Insiders sold $30.1M of stock over the last 18 months across 11 sales and made no open-market purchases; those sales are often planned in advance or made to cover taxes on vesting shares.
CleaRank score 71/100 (Buy). 15 of 19 checks pass: trend 4 of 4, momentum 2 of 3, valuation and quality 4 of 5, analysts 1 of 3, track record 4 of 4.
About Amgen
Amgen Inc. , a biotechnology company focused on discovering, developing, manufacturing, and marketing human therapeutics for serious diseases. The company’s portfolio spans therapies used in oncology, inflammation, cardiovascular conditions, osteoporosis, and rare diseases, making it a significant participant in global biopharmaceutical markets. Amgen also supports its business through biologic manufacturing capabilities and a commercial organization that brings prescription medicines to patients and healthcare providers in multiple regions. As a large-cap healthcare equity, Amgen Inc.
AMGN stock news
Earnings beat and rise
·Earnings report
Adjusted EPS of $6.45 beat the $5.78 estimate by 11.59%, and the shares rose 3.73% in the next session. This is the clearest recent evidence that results are running ahead of expectations.
Buy rating kept by Argus
·Argus Research
Argus Research kept its Buy rating on November 12, 2026, a supportive view as the stock works through its recent pullback.
Downgrade to Hold
·Freedom Broker
Freedom Broker cut its rating to Hold from Buy on November 6, 2026, reducing the number of buy-side voices at a time when the stock is near the median target.
Buy rating held by UBS
·UBS
UBS kept its Buy rating on November 4, 2026, one of several reiterations that show analysts remain divided rather than moving toward a clear consensus.
Hold ratings maintained
·Canaccord Genuity
Leerink Partners, Guggenheim and Canaccord Genuity all kept their non-buy ratings in early November, so the majority view is still neutral.
AMGN price target 2026
The base case is that Amgen keeps growing earnings in line with its estimates while the stock trades near the analysts' median target. Analysts expect EPS to rise 7.8% this fiscal year to $23.53 and 6.4% next year to $25.04, and revenue to grow 7.5% to $39.5B this year. A stock priced close to the median target leaves limited room for a re-rating unless those estimates move up. The bull case needs continued beats, like the 11.59% beat in November, and a return toward the 52-week high of $483.99. The bear case is a loss of the 50-day average at $430.45, which would bring the 200-day average at $383.40 into view, or a further downgrade following the November 6 cut to Hold by Freedom Broker. Simulations from past volatility are not forecasts, and the typical daily move of 1.73% means large swings remain normal.
Analyst targets and ratings
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Nov 12, 2026 | Argus Research | Maintains | Buy |
| Nov 6, 2026 | Freedom Broker | Downgrade | Hold |
| Nov 5, 2026 | Leerink Partners | Maintains | Market Perform |
| Nov 5, 2026 | Guggenheim | Maintains | Neutral |
| Nov 4, 2026 | Canaccord Genuity | Maintains | Hold |
| Nov 4, 2026 | UBS | Maintains | Buy |
AMGN support and resistance levels
Support sits first at the 50-day simple moving average of $430.45, which the price is just above, followed by the 200-day simple moving average of $383.40. The 52-week low of $312.39 is the deepest reference below the price. Resistance comes first from the 20-day exponential moving average at $451.57, which the price is below, then the 52-week high of $483.99. A close back above the 20-day average would be the first sign the recent drop is being reversed, while the 50-day average marks where buyers have defended the stock recently.
| Level | What it is | Price | From the price |
|---|---|---|---|
| Resistance 2 | 52-week high | $483.99 | +11.1% |
| Resistance 1 | 20-day exponential average | $451.57 | +3.7% |
| Price | November 20, 2026 | $435.64 | |
| Support 1 | 50-day moving average | $430.45 | -1.2% |
| Support 2 | 200-day moving average | $383.40 | -12.0% |
| Support 3 | 52-week low | $312.39 | -28.3% |
Technical indicators
AMGN technical analysis in depth
Volatility, momentum, trend strength and the price levels that matter for AMGN, calculated by CleaRank from daily bars to November 20, 2026.
Volatility
On the 20-day Bollinger Bands (2 standard deviations) the bands run from $436.82 to $479.87 around a middle of $458.35, and AMGN's close of $435.64 sits below the lower band, a stretched reading.
Band width is 9.4% of the price, in the middle of its range over the last 120 sessions.
The 14-day average true range is $11.58, or 2.7% of the price: a typical day's swing from high to low. A stop placed 1.5 ATR away would sit about 4.0% from the close.
Momentum and volume
The 14-day stochastic reads 2 (signal line 5): the close is near the bottom of its two-week range, an oversold zone.
The MACD line (12, 26) is 3.51 against a signal line (9) of 8.53, so the histogram is negative: momentum is weakening relative to its recent average. The MACD line crossed below its signal line 6 sessions ago.
Volume in the latest session was 1.9 times its 20-day average, heavy enough to give the move more weight.
Trend strength
The 14-day ADX is 29: a trending market, with sellers in control (+DI 25, -DI 25).
On the weekly chart the 10-week average ($431.77) is above the 40-week average ($383.85), a rising longer-term trend, and the weekly RSI is 57.
Key levels
The nearest resistance from the price history is $446.63 (+2.5%): the price turned here 3 times, most recently on November 6, 2026.
The nearest support is $426.59 (-2.1%): a swing low set on September 30, 2026.
The largest swing of the last 120 sessions ran up from $325.98 (June 3, 2026) to $483.99 (November 5, 2026); the nearest Fibonacci retracement to the price is the 23.6% level at $446.70.
Classic pivot points for the next session, from November 20, 2026: pivot $438.55, resistance $442.58 and $449.53, support $431.60 and $427.57.
| Level | Price | From the price | What it is |
|---|---|---|---|
| Resistance (swing high) | $483.99 | +11.1% | a swing high set on November 5, 2026 |
| Upper Bollinger Band | $479.87 | +10.2% | 20-day average + 2 standard deviations |
| Pivot R2 (classic) | $449.53 | +3.2% | next-session level |
| Fibonacci 23.6% | $446.70 | +2.5% | retracement of the rise from $325.98 to $483.99 |
| Resistance (swing high) | $446.63 | +2.5% | the price turned here 3 times, most recently on November 6, 2026 |
| Pivot R1 (Fibonacci) | $442.74 | +1.6% | 38.2% of the last range above the pivot |
| Pivot R1 (classic) | $442.58 | +1.6% | next-session level |
| Pivot point | $438.55 | +0.7% | average of the last high, low and close |
| Lower Bollinger Band | $436.82 | +0.3% | 20-day average - 2 standard deviations |
| Price | $435.64 | close, November 20, 2026 | |
| Pivot S1 (Fibonacci) | $434.35 | -0.3% | 38.2% of the last range below the pivot |
| Pivot S1 (classic) | $431.60 | -0.9% | next-session level |
| Pivot S2 (classic) | $427.57 | -1.9% | next-session level |
| Support (swing low) | $426.59 | -2.1% | a swing low set on September 30, 2026 |
| Fibonacci 38.2% | $423.63 | -2.8% | retracement of the rise from $325.98 to $483.99 |
| Fibonacci 50.0% | $404.99 | -7.0% | retracement of the rise from $325.98 to $483.99 |
| Support (swing low) | $395.10 | -9.3% | the price turned here 3 times, most recently on October 6, 2026 |
| Fibonacci 61.8% | $386.34 | -11.3% | retracement of the rise from $325.98 to $483.99 |
| Support (swing low) | $378.74 | -13.1% | the price turned here 4 times, most recently on September 16, 2026 |
| Fibonacci 78.6% | $359.79 | -17.4% | retracement of the rise from $325.98 to $483.99 |
Swing levels are highs and lows the price turned at (the extreme of the five sessions either side), merged when they sit within 1.2 average true ranges of each other. Bollinger Bands (20, 2), ATR (14, Wilder), stochastic (14, 3), MACD (12, 26, 9), ADX (14, Wilder). Readings describe the chart; they are not a forecast.
AMGN stock price and trading
AMGN share price
AMGN fundamentals and valuation
Key statistics
AMGN against the Healthcare sector
Price to earnings vs sector: AMGN trades at a notable discount to sector peers (-21% against the sector median P/E). Investors are paying less for each dollar of earnings than for the typical stock in the sector.
Return vs XLV: Since Jun 11, 2025, AMGN has gained 49.3% against a gain of 30.6% for XLV.
Performance against XLV
Revenue and earnings
Revenue growth: Revenue grew 10.0% in FY2025 to $36.8B, from $33.4B a year earlier.
Profit margin: The net margin was 21.0% in FY2025, up from 12.2% the year before.
Profitable: AMGN earned $7.7B in FY2025.
Earnings reality check
Earnings record: AMGN beat the analyst estimate in 8 of the last 8 quarters.
Market reaction: The stock fell in the first session after 3 of those 8 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Nov 3, 2026after close | $5.78 | $6.45 | +11.59% | +3.73% | +0.86% |
| Aug 4, 2026after close | $5.62 | $6.29 | +11.92% | +4.57% | +6.23% |
| Apr 30, 2026after close | $4.77 | $5.15 | +7.97% | -4.75% | -4.96% |
| Feb 3, 2026after close | $4.73 | $5.29 | +11.84% | +8.15% | +7.70% |
| Nov 4, 2025after close | $5.01 | $5.64 | +12.57% | +7.81% | +14.07% |
| Aug 5, 2025after close | $5.28 | $6.02 | +14.02% | -5.14% | -5.03% |
| May 1, 2025after close | $4.26 | $4.90 | +15.02% | -0.90% | -4.13% |
| Feb 4, 2025after close | $5.08 | $5.31 | +4.53% | +6.50% | +2.64% |
AMGN price history and drawdowns
Risk profile
Worst falls and recoveries
Growth of $10,000
Against the market: AMGN beat the S&P 500 over this period: $41,120 against $36,764.
A $10,000 investment in AMGN in December 2016 would be worth about $41,120 today with dividends reinvested, compared with about $36,764 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
AMGN stock price prediction 2030
AMGN Stock Price Prediction 2030: Simulated Scenarios
CleaRank's simulation projects a price near $599 for AMGN by 2030 in the base case, from $436 today (1.4x over 4 years). The 10th-percentile path ends near $315. These are outcomes of a Monte Carlo simulation run on AMGN's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $342 | $472 | $651 | |
| 2028 | $324 | $511 | $805 | |
| 2029 | $317 | $553 | $966 | |
| 2030 | $315 | $599 | $1,140 |
AMGN insider trading
AMGN insider trading
Month by month
Net insider selling: No insider bought AMGN shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Nov 6, 2026 | Michael V Drake
Director
|
Grant | 114 | - |
| Nov 6, 2026 | David W Gibbs
Director
|
Grant | 278 | - |
| Nov 6, 2026 | Charles M Holley Jr
Director
|
Grant | 184 | - |
| Nov 6, 2026 | Omar Syed Ishrak
Director
|
Grant | 152 | - |
| Aug 13, 2026 | Rachna Khosla
Officer
|
Sell | 3.3K | $1.3M |
| Aug 13, 2026 | Rachna Khosla
Officer
|
Option | 1.3K | $203.6K |
| Aug 7, 2026 | Matthew C. Busch
Officer
|
Grant | 730 | - |
| Aug 7, 2026 | Michael V Drake
Director
|
Grant | 63 | - |
| Aug 7, 2026 | Charles M Holley Jr
Director
|
Grant | 103 | - |
| Aug 7, 2026 | Omar Syed Ishrak
Director
|
Grant | 85 | - |
AMGN stock forecast: questions people ask
AMGN Forecast: Frequently Asked Questions
What is the AMGN stock forecast?
What is the AMGN price target?
Is AMGN a buy or sell today?
How has Amgen's earnings record held up?
Why is AMGN trading below its 52-week high?
How does AMGN's valuation compare with its sector?
How these figures are computed, and where the data comes from: CleaRank methodology.